Literature DB >> 29248179

Association of time-to-surgery with outcomes in clinical stage I-II pancreatic adenocarcinoma treated with upfront surgery.

Douglas S Swords1, Chong Zhang2, Angela P Presson2, Matthew A Firpo3, Sean J Mulvihill3, Courtney L Scaife3.   

Abstract

BACKGROUND: Time-to-surgery from cancer diagnosis has increased in the United States. We aimed to determine the association between time-to-surgery and oncologic outcomes in patients with resectable pancreatic ductal adenocarcinoma undergoing upfront surgery.
METHODS: The 2004-2012 National Cancer Database was reviewed for patients undergoing curative-intent surgery without neoadjuvant therapy for clinical stage I-II pancreatic ductal adenocarcinoma. A multivariable Cox model with restricted cubic splines was used to define time-to-surgery as short (1-14 days), medium (15-42), and long (43-120). Overall survival was examined using Cox shared frailty models. Secondary outcomes were examined using mixed-effects logistic regression models.
RESULTS: Of 16,763 patients, time-to-surgery was short in 34.4%, medium in 51.6%, and long in 14.0%. More short time-to-surgery patients were young, privately insured, healthy, and treated at low-volume hospitals. Adjusted hazards of mortality were lower for medium (hazard ratio 0.94, 95% confidence interval, .90, 0.97) and long time-to-surgery (hazard ratio 0.91, 95% confidence interval, 0.86, 0.96) than short. There were no differences in adjusted odds of node positivity, clinical to pathologic upstaging, being unresectable or stage IV at exploration, and positive margins. Medium time-to-surgery patients had higher adjusted odds (odds ratio 1.11, 95% confidence interval, 1.03, 1.20) of receiving an adequate lymphadenectomy than short. Ninety-day mortality was lower in medium (odds ratio 0.75, 95% confidence interval, 0.65, 0.85) and long time-to-surgery (odds ratio 0.72, 95% confidence interval, 0.60, 0.88) than short.
CONCLUSION: In this observational analysis, short time-to-surgery was associated with slightly shorter OS and higher perioperative mortality. These results may suggest that delays for medical optimization and referral to high volume surgeons are safe. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2017        PMID: 29248179     DOI: 10.1016/j.surg.2017.10.054

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  8 in total

1.  Gastrointestinal Malignancies and the COVID-19 Pandemic: Evidence-Based Triage to Surgery.

Authors:  Scott C Fligor; Sophie Wang; Benjamin G Allar; Savas T Tsikis; Ana Sofia Ore; Ashlyn E Whitlock; Rodrigo Calvillo-Ortiz; Kevin R Arndt; Sidhu P Gangadharan; Mark P Callery
Journal:  J Gastrointest Surg       Date:  2020-06-30       Impact factor: 3.452

Review 2.  An update on treatment options for pancreatic adenocarcinoma.

Authors:  Aurélien Lambert; Lilian Schwarz; Ivan Borbath; Aline Henry; Jean-Luc Van Laethem; David Malka; Michel Ducreux; Thierry Conroy
Journal:  Ther Adv Med Oncol       Date:  2019-09-25       Impact factor: 8.168

Review 3.  ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer.

Authors:  Silvia Catanese; George Pentheroudakis; Jean-Yves Douillard; Florian Lordick
Journal:  ESMO Open       Date:  2020-05

4.  Time interval from last visit to imaging diagnosis influences outcome in pancreatic adenocarcinoma: A regional population-based study on linked medico-administrative and clinical data.

Authors:  Vittoria Balzano; Emeline Laurent; Aline-Marie Florence; Anne-Isabelle Lecuyer; Carole Lefebvre; Patrick Heitzmann; Pascal Hammel; Thierry Lecomte; Leslie Grammatico-Guillon
Journal:  Ther Adv Med Oncol       Date:  2022-09-05       Impact factor: 5.485

5.  [Strategy for the practice of digestive and oncologic surgery in COVID-19 epidemic situation].

Authors:  J-J Tuech; A Gangloff; F Di Fiore; P Michel; C Brigand; K Slim; M Pocard; L Schwarz
Journal:  J Chir Visc       Date:  2020-03-31

6.  Strategy for the practice of digestive and oncological surgery during the Covid-19 epidemic.

Authors:  J-J Tuech; A Gangloff; F Di Fiore; P Michel; C Brigand; K Slim; M Pocard; L Schwarz
Journal:  J Visc Surg       Date:  2020-03-31       Impact factor: 2.043

7.  Impact of time interval between multidisciplinary team meeting and intended pancreatoduodenectomy on oncological outcomes.

Authors:  M W Steen; L B van Rijssen; S Festen; O R Busch; B Groot Koerkamp; L G van der Geest; I H de Hingh; H C van Santvoort; M G Besselink; M F Gerhards
Journal:  BJS Open       Date:  2020-08-25

8.  Time from first seen in specialist care to surgery does not influence survival outcome in patients with upfront resected pancreatic adenocarcinoma.

Authors:  M Brugel; O Bouché; R Kianmanesh; L Teuma; A Tashkandi; J M Regimbeau; P Pessaux; B Royer; R Rhaiem; C Perrenot; C Neuzillet; T Piardi; S Deguelte
Journal:  BMC Surg       Date:  2021-12-07       Impact factor: 2.102

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.